Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

A proposed 25% tariff on U.S. pharmacy imports would drive up U.S. drug costs by $51 billion annually, according to an analysis by Ernst & Young reviewed by Reuters. The April 22 analysis, ...

The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for ...